[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-445778-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-445778-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","access-to-medications-for-chronic-degenerative-and-rare-diseases-in-the-brazilian-public-health-system-pd68","Access To Medications For Chronic Degenerative And Rare Diseases In The Brazilian Public Health System - PD68","","Study evaluates access to medicines for chronic degenerative and rare diseases provided by Brazil’s Unified Health System (SUS) via the Specialized Component of Pharmaceutical Assistance (CEAF) from 2012 to 2023. Using administrative national dispensing data from the Health Intelligence Open Situation Platform (SABEIS) updated in August 2024, the annual number of CEAF users was assessed after CONITEC establishment in 2012. Results show continuous user growth, with stabilization during 2019–2020, followed by accelerated expansion from 2021.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/access-to-medications-for-chronic-degenerative-and-rare-diseases-in-the-brazilian-public-health-system-pd68/445778/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/access-to-medications-for-chronic-degenerative-and-rare-diseases-in-the-brazilian-public-health-system-pd68/445778.png","ImageObject",300,407,{"name":42,"@type":43},"Genevieve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the focus of PD68 in the study?","Question",{"text":63,"@type":64},"PD68 analyzes the number of people who accessed medicines included in CEAF for chronic degenerative and rare diseases in Brazil’s SUS from 2012 to 2023.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which data source and period were used to assess CEAF access?",{"text":68,"@type":64},"Administrative and national dispensing data were extracted from SABEIS covering January 2012 to December 2023, with data updated in August 2024.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main findings about CEAF users from 2012 to 2023?",{"text":72,"@type":64},"CEAF users increased continuously, rising from 1,991,828 in 2012 to 3,783,957 in 2023 (about a 90% increase), with stabilization during 2019–2020 and faster growth from 2021 onward.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},445778,1790817627,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":22,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":30,"preview_page_count":4},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","PD68 Access To Medications For Chronic Degenerative And Rare Diseases In The Brazilian Public Health System: 2012 to 2023  \nAmanda Oliveira Lyrio ([amanda.lyrio@saude.gov.br](amanda.lyrio@saude.gov.br)), Ana Carolina de Freitas Lopes and Luciene Bonan  \nIntroduction: Medications for chronic degenerative and rare diseases are provided by the Brazilian Unified Health System (SUS) after health technology assessment analysis conducted by the National Committee for Health Technology Incorporation (CONITEC) . Access to these medicines at an outpatient level occurs through the Specialized Component of Pharmaceutical Assistance (CEAF) . This study analyzed the number of people who had access to medicines included in the CEAF from 2012 to 2023 .  \nMethods: Administrative and national dispensing data were extracted from the Health Intelligence Open Situation Platform (SABEIS), covering the period from January 2012 to December 2023, with data updated in August 2024 . SABEIS consolidates open data from Ambulatory Information System (SIA/SUS), providing anonymized, individualized data. The annual number of users receiving medications from the CEAF was evaluated over this period, starting from the establishment of CONITEC in 2012 .  \nResults: Findings indicated a continuous growth in CEAF users between 2012 and 2023, with a total of 10,969,433 users and 84 different clinical conditions. The number of users grew from 1,991,828 in 2012 to 3,783,957 in 2023, reflecting an approximate 90 percent increase over 12 years and an average annual increase of 163,000 new users. During2019and2020, there was stabilization, with only11,332 new users, potentially duetothe impact ofCOVID-19 on distribution and access. From 2021 onward, growth accelerated, with annual additions of 200,000 to 350,000 users, suggesting a recovery and expansion in treatment coverage.  \nConclusions: The data highlighted an increasing demand for specialized treatments and the impact of CONITEC’s decisions on expanding access to high-cost treatments for chronic-degenerative and rare diseases in the Brazilian SUS.  \nPD69 Mental Health And The Use Of Antidepressants In Brazilian Media: A Content Analysis Using Natural Language Processing Tools  \nSabrina Wolenski Bartoszewski, William Jorge Pereira, Aline Verderamis, Cristiane De Cassia Bergamaschi Motta, Silvio Barberato-Filho, Luciane Lopes,  \nLuis Gustavo Modelli de Andrade and  \nJuliana Machado-Rugolo ([jr.machado@unesp.br](jr.machado@unesp.br))  \nIntroduction: Despite the significant impact of the media on individuals with mental illness, newspaper articles related to antidepressants have not been systematically studied. The present study aimed to analyze Brazilian journalistic coverage on the use of antidepressants to understand how the news presents and shapes the topic of antidepressants for its readers.  \nMethods: This qualitative study evaluated journalistic content on antidepressant use from Folha de São Paulo, a newspaper available in digital format. Articles published between 1 January 2019 and 31 December 2023 were collected and stored in a database for analysis. Natural language processing (NLP) techniques, combined with machine learning, were applied. The R software (version 4.3.3) with tidytext, tm, tidyverse, and stringr packages was used for the analyses. The study identified patterns and trends in language usage, focusing on frequently occurring terms to understand how antidepressants are portrayed in media content.  \nResults: The initial research was conducted using the keyword“antidepressants” in the search engine of the Folha de São Paulo. Of the articles assessed for eligibility, 182 were included in the study. Across all the articles, the analysis aimed to identify the most frequently used words, resulting in a word cloud. The most used words in the text body were “treatment,” followed by “years,” “anxiety,”“women,” and “pandemic.” Regarding the most frequent words in the titles, they were “depression,” “heal","cbCairCX7Q16TVo3","https://ap.wps.com/l/cbCairCX7Q16TVo3","pdf",29573,"English","# Introduction\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What is the focus of PD68 in the study?\",\"answer\":\"PD68 analyzes the number of people who accessed medicines included in CEAF for chronic degenerative and rare diseases in Brazil’s SUS from 2012 to 2023.\"},{\"question\":\"Which data source and period were used to assess CEAF access?\",\"answer\":\"Administrative and national dispensing data were extracted from SABEIS covering January 2012 to December 2023, with data updated in August 2024.\"},{\"question\":\"What were the main findings about CEAF users from 2012 to 2023?\",\"answer\":\"CEAF users increased continuously, rising from 1,991,828 in 2012 to 3,783,957 in 2023 (about a 90% increase), with stabilization during 2019–2020 and faster growth from 2021 onward.\"}]","Access To Medications For Chronic Degenerative And Rare Diseases In The Brazilian Public Health System - PD68 | PDF",1790712677]